Title: A Comparative Study of Clinical Outcome of Use of Topical 2% Sertaconazole Versus 1% Terbinafineas Monotherapy in the Treatment of Tinea Corporis
Authors: Manogna Vellala, Janardhan Bommakanti, Sindhuri Vongumalli
DOI: https://dx.doi.org/10.18535/jmscr/v4i11.92
Abstract
Tinea corporis, a superficial fungal infection caused by dermatophytes is highly prevalent in India. This condition primarily affects the limbs and the trunk and can severely impair the quality of life of the patient.
Aim: To compare the outcome of use of Terbinafine and Sertaconazole as monotherapy in the treatment of tinea corporis.
Materials and Methods: 58 patients were enrolled in this single blind parallel therapeutic trial.The patients were allocated to each arm of the study by stratified random sampling. Group A received treatment with Sertaconazole nitrate 2 % cream while group B received treatment with terbinafine hydrochloride 1% cream twice daily. The patients were reviewed weekly for 4 weeks and followed up for 2 weeks after completion of treatment. The primary outcome measures were percentage of patients showing clinical and mycological cure while mean improvement in clinical score was a secondary outcome measure.
Results: 50 patients out of 58 completed the study,25 in each arm. Between the two arms, more percentage of patients in the Sertaconazole arm showed mycological clearance at weeks 2 and 3(48 and 76%) compared to Terbinafine (28 & 68%) respectively. A significantly larger number of patients in the Sertaconazole arm showed complete or near complete improvement in clinical scores(84%) at week 3 compared to those in the Terbinafine arm (68%). The mean improvement in clinical scores was significantly higher for the patients in the Sertaconazole arm at weeks 2 and 3.
Conclusion: Sertaconazole showed faster mycological clearance and could achieve better percentage of clinical cure in a shorter duration when compared to terbinafine.
KEYWORDS: Sertaconazole, Terbinafine, tinea corporis, topical antifungals, monotherapy.
References
1. B. Havlickova, V. A. Czaika, and M. Friedrich, “Epidemiological trends in skin mycoses worldwide,” Mycoses, vol. 51, no. 4, pp. 2–15, 2008
2. Weitzman, I., & Summerbell, R. C. (1995). The dermatophytes. Clinical Microbiology Reviews, 8(2), 240–259.
3. S. Balakumar, S. Rajan, T. Thirunalasundari, and S. Jeeva, “Epidemiology of dermatophytosis in and around Tiruchirapalli, Tamilnadu, India,” Asian Pacific Journal of Tropical Disease, vol. 2, no. 4, pp. 286–289, 2012.
4. Madhavi S, Rama Rao MV, Jyothsna K. Mycological study of dermatophytosis in rural population. Ann Biol Res. 2011;2 (3):88–93
5. Bhatia VK, Sharma PC. Epidemiological studies on Dermatophytosis in human patients in Himachal Pradesh, India. SpringerPlus. 2014;3:134. doi:10.1186/2193-1801-3-134.
6. Peerapur B V, Inamdar A C, Pushpa P V, Srikant B. Clinicomycological study of dermatophytosis in Bijapur. Indian J Med Microbiol [serial online] 2004 [cited 2016 Nov 18];22:273-4. Available from: http://www.ijmm.org/text.asp?2004/22/4/273/12826
7. Griffiths C. Rook's textbook of dermatology. 9th ed. 2016.John Wiley & Sons,Ltd.p32.37
8. Wolverton,Comprehensive dermatological drug therapy.3rd ed.
9. Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NLMC, Correr CJ. Efficacy of Topical Antifungals in the Treatment of DermatophytosisA Mixed-Treatment Comparison Meta-analysis Involving 14 Treatments. JAMA Dermatol. 2013;149(3):341-349. doi:10.1001/jamadermatol.2013.1721
10. Sharma, A., Saple, D. G., Surjushe, A., Rao, G. R. R., Kura, M., Ghosh, S., Bolmall, C. and Baliga, V. (2011), Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. Mycoses, 54: 217–222. doi:10.1111/j.1439-0507.2009.01801
11. Khan HS, Dudhgaonkar S, Bende MM, Wankhede S. Comparison of efficacy, safety and cost-effectiveness of clotrimazole 1% cream and sertaconazole 2% cream in patients suffering from of mild to moderate tinea corporis, attending tertiary care hospital out-patient department: a randomized, open-labeled, comparative, parallel group trial. Int J Basic Clin Pharmacol. (2015), [cited November 18, 2016]; 4(1): 75-81. doi:10.5455/2319-2003.ijbcp20150214
12. Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NLMC, Correr CJ. Efficacy of Topical Antifungals in the Treatment of DermatophytosisA Mixed-Treatment Comparison Meta-analysis Involving 14 Treatments. JAMA Dermatol. 2013;149(3):341-349. doi:10.1001/jamadermatol.2013.1721
13. KAGAWA, S. (1989), Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clinical and Experim-ental Dermatology, 14: 114–115. doi:10.1111/j.1365-2230.1989.tb00905.
14. Choudhary SV, Bisati S, Singh AL, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: A comparative therapeutic trial. Indian J Dermatol 2013; 58:457-60.
15. A.Tamil Selvan,Gutha Girisha, Vijayabhaskar ,R. Suthakaran,Comparitive study of newer antifungals in the treatment of superficial fungal infections.Int. Res.J. Pharm,2013.:4(6),224-228.
16. Sumitha A, Geetha M, Shashikala GH, Somashekar HS, Chandan KS. Efficacy and safety of 1% terbinafine hydrochloride versus 2% sertaconazole cream in the treatment of tinea corporis. Int J Basic Clin Pharmacol 2015; 4:474-8.
17. Jerajani HR, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. Indian J Dermatol 2013; 58:34-8.